|
Mechanismfungal CYP51A1 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date21 Dec 1995 |
硝酸布康唑阴道凝胶治疗外阴阴道假丝酵母菌病有效性安全性,随机单盲阳性药平行对照、多中心临床试验
[Translation] The efficacy and safety of butoconazole nitrate vaginal gel in the treatment of vulvovaginal candidiasis: a randomized, single-blind, positive-drug parallel-controlled, multicenter clinical trial
进一步评价硝酸布康唑阴道凝胶治疗外阴阴道假丝酵母菌病(VVC)的有效性和安全性。
[Translation] To further evaluate the efficacy and safety of butoconazole nitrate vaginal gel in the treatment of vulvovaginal candidiasis (VVC).
硝酸布康唑阴道凝胶治疗外阴阴道假丝酵母菌病有效性和安全性,随机单盲、阳性药平行对照、多中心临床试验
[Translation] Efficacy and safety of butoconazole nitrate vaginal gel in the treatment of vulvovaginal candidiasis: a randomized, single-blind, active-drug parallel-controlled, multicenter clinical trial
评价硝酸布康唑阴道凝胶治疗外阴阴道假丝酵母菌病的有效性、安全性,为Ⅱb期临床试验提供最佳给药方案依据
[Translation] To evaluate the efficacy and safety of butoconazole nitrate vaginal gel in the treatment of vulvovaginal candidiasis and provide the basis for the best dosing regimen for phase IIb clinical trials
100 Clinical Results associated with Jinan Hongruichuangbo Pharmaceutical Technology Development Co., Ltd.
0 Patents (Medical) associated with Jinan Hongruichuangbo Pharmaceutical Technology Development Co., Ltd.
100 Deals associated with Jinan Hongruichuangbo Pharmaceutical Technology Development Co., Ltd.
100 Translational Medicine associated with Jinan Hongruichuangbo Pharmaceutical Technology Development Co., Ltd.